S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
Log in
NASDAQ:CRVS

Corvus Pharmaceuticals Stock Forecast, Price & News

$2.86
-0.02 (-0.69 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.83
Now: $2.86
$2.97
50-Day Range
$2.88
MA: $3.76
$4.77
52-Week Range
$1.01
Now: $2.86
$6.88
Volume929,906 shs
Average Volume1.12 million shs
Market Capitalization$80.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.
Corvus Pharmaceuticals logo

Headlines

Is CRVS A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
Corvus' immunotherapy shows durable benefit in COVID-19
November 9, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520
Employees52
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.42 per share

Profitability

Net Income$-46,670,000.00

Miscellaneous

Market Cap$80.26 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

134th out of 1,971 stocks

Pharmaceutical Preparations Industry

58th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
$2.86
-0.02 (-0.69 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

Is Corvus Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Corvus Pharmaceuticals?

Wall Street analysts have given Corvus Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corvus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Thursday, October, 29th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.09.
View Corvus Pharmaceuticals' earnings history
.

How has Corvus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRVS shares have increased by 5.5% and is now trading at $2.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRVS?

3 brokers have issued 1 year price targets for Corvus Pharmaceuticals' stock. Their forecasts range from $4.00 to $12.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 179.7% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 70, Pay $303k)
  • Dr. Peter A. Thompson, Co-Founder & Independent Director (Age 61, Pay $47k)
  • Mr. Leiv Lea, Chief Financial Officer (Age 67, Pay $352.31k)
  • Dr. Mehrdad Mobasher M.D., M.P.H., VP & Chief Medical Officer (Age 48, Pay $654.73k)
  • Ms. Debra Horen SPHR, VP of HR
  • Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 55)
  • Mr. Alan C. Mendelson Esq., Sec.
  • Stephen Willingham, Sr. Scientist

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corvus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.84%), CHI Advisors LLC (1.75%), BlackRock Inc. (0.25%), Truist Financial Corp (0.07%) and Golden Green Inc. (0.07%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals
.

Which major investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including CHI Advisors LLC, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Corvus Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Corvus Pharmaceuticals stock?

CRVS stock was bought by a variety of institutional investors in the last quarter, including Truist Financial Corp, and Golden Green Inc.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $2.86.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals has a market capitalization of $80.26 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals employs 52 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Where are Corvus Pharmaceuticals' headquarters?

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]


This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.